Persistencia de tratamiento con antagonistas del factor de necrosis tumoral frente a antagonistas de interleucinas en psoriasis moderada-grave

Sáez-Belló, M; Climente Martí, M; Llopis Salvia, P; Santos Alarcón, S; Sanchís-Sánchez, C; Gómez Herrero, D; Mateu Puchades, A.
O.F.I.L ; 31(4): 361-368, 2021. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-224751

Documentos relacionados

  1. Anti-tumour necrosis factor-induced skin rashes in inflammatory bowel disease: a systematic review and evidence-based management algorithm.
  2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
  3. Long lasting response to anti-tumor necrosis factor α agents in psoriasis: A real life experience.
  4. Pharmacogenetics Update on Biologic Therapy in Psoriasis.
  5. Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study.
  6. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
  7. Biological treatment in severe psoriasis: Influence on peripheral blood dendritic cells.
  8. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
  9. Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature.
  10. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.